Citi opens ‘positive catalyst watch’ on Establishment Labs

Citi analyst Joanne Wuensch opened a “90-day positive catalyst watch” on shares of Establishment Labs while keeping a Neutral rating on the name with a $45 price target. Management is making progress towards FDA approval of Motiva, the analyst tells investors in a research note. With the short interest in the stock remaining high at 19%, Citi suspects a positive sign from the FDA could lead to a “short squeeze.”